J E Polifka

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. ncbi Developmental toxicity of ribavirin/IFalpha combination therapy: is the label more dangerous than the drugs?
    Janine E Polifka
    Birth Defects Res A Clin Mol Teratol 67:8-12. 2003
  2. ncbi Is there an embryopathy associated with first-trimester exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists? A critical review of the evidence
    Janine E Polifka
    Department of Pediatrics, University of Washington, Seattle, Washington, USA
    Birth Defects Res A Clin Mol Teratol 94:576-98. 2012
  3. ncbi Developmental toxicity: web resources for evaluating risk in humans
    Janine E Polifka
    Department of Pediatrics, TERIS Project, University of Washington, PO Box 357920, Seattle, WA 98195 7920, USA
    Toxicology 173:35-65. 2002
  4. ncbi Teratogen update: azathioprine and 6-mercaptopurine
    Janine E Polifka
    TERIS Project, University of Washington, Seattle 98195-7920, USA
    Teratology 65:240-61. 2002
  5. ncbi Medical genetics: 1. Clinical teratology in the age of genomics
    Janine E Polifka
    Department of Pediatrics, University of Washington, Seattle, USA
    CMAJ 167:265-73. 2002
  6. ncbi Postmarketing surveillance for human teratogenicity: a model approach
    C D Chambers
    Department of Pediatrics, University of California, San Diego, CA 92103 8446, USA
    Teratology 64:252-61. 2001
  7. ncbi Update on new developments in the study of human teratogens
    T H Shepard
    University of Washington, Department of Pediatrics, Seattle, Washington 98195 6320, USA
    Teratology 65:153-61. 2002
  8. ncbi Drug safety in pregnant women and their babies: ignorance not bliss
    C D Chambers
    Department of Pediatrics, University of California, San Diego School of Medicine, La Jolla, California, USA
    Clin Pharmacol Ther 83:181-3. 2008
  9. ncbi Addendum: sartan treatment during pregnancy
    Sura Alwan
    Department of Medical Genetics, University of British Columbia, Vancouver, Canada
    Birth Defects Res A Clin Mol Teratol 73:904-5. 2005
  10. ncbi A survey of pregnant women using isotretinoin
    Julia Robertson
    Utah Department of Health, Division of Community and Family Health Services, Birth Defects and Genetics Program, Pregnancy RiskLine, Salt Lake City, 84114 4691, USA
    Birth Defects Res A Clin Mol Teratol 73:881-7. 2005

Detail Information

Publications11

  1. ncbi Developmental toxicity of ribavirin/IFalpha combination therapy: is the label more dangerous than the drugs?
    Janine E Polifka
    Birth Defects Res A Clin Mol Teratol 67:8-12. 2003
  2. ncbi Is there an embryopathy associated with first-trimester exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists? A critical review of the evidence
    Janine E Polifka
    Department of Pediatrics, University of Washington, Seattle, Washington, USA
    Birth Defects Res A Clin Mol Teratol 94:576-98. 2012
    ....
  3. ncbi Developmental toxicity: web resources for evaluating risk in humans
    Janine E Polifka
    Department of Pediatrics, TERIS Project, University of Washington, PO Box 357920, Seattle, WA 98195 7920, USA
    Toxicology 173:35-65. 2002
    ....
  4. ncbi Teratogen update: azathioprine and 6-mercaptopurine
    Janine E Polifka
    TERIS Project, University of Washington, Seattle 98195-7920, USA
    Teratology 65:240-61. 2002
  5. ncbi Medical genetics: 1. Clinical teratology in the age of genomics
    Janine E Polifka
    Department of Pediatrics, University of Washington, Seattle, USA
    CMAJ 167:265-73. 2002
    ..We discuss general principles of risk counselling and risk reduction, and we describe several long-known teratogens, as well as several exposures recognized only recently to have teratogenic potential...
  6. ncbi Postmarketing surveillance for human teratogenicity: a model approach
    C D Chambers
    Department of Pediatrics, University of California, San Diego, CA 92103 8446, USA
    Teratology 64:252-61. 2001
    ..The purpose of this report is to outline a complementary approach that can be used in addition to other more established methods to provide the most comprehensive evaluation of prenatal exposures with respect to teratogenicity...
  7. ncbi Update on new developments in the study of human teratogens
    T H Shepard
    University of Washington, Department of Pediatrics, Seattle, Washington 98195 6320, USA
    Teratology 65:153-61. 2002
    ..The purpose of this annual article is to highlight and briefly review new and significant information on agents that may be teratogenic in pregnant women. Various sources of on-line and printed information are given...
  8. ncbi Drug safety in pregnant women and their babies: ignorance not bliss
    C D Chambers
    Department of Pediatrics, University of California, San Diego School of Medicine, La Jolla, California, USA
    Clin Pharmacol Ther 83:181-3. 2008
    ....
  9. ncbi Addendum: sartan treatment during pregnancy
    Sura Alwan
    Department of Medical Genetics, University of British Columbia, Vancouver, Canada
    Birth Defects Res A Clin Mol Teratol 73:904-5. 2005
  10. ncbi A survey of pregnant women using isotretinoin
    Julia Robertson
    Utah Department of Health, Division of Community and Family Health Services, Birth Defects and Genetics Program, Pregnancy RiskLine, Salt Lake City, 84114 4691, USA
    Birth Defects Res A Clin Mol Teratol 73:881-7. 2005
    ..Isotretinoin is a known human teratogen, causing birth defects and/or subnormal cognitive performance in prenatally-exposed children...
  11. ncbi Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases
    Joseph Lam
    Department of Pediatrics, Division of Dermatology, Rady Children s Hospital, University of California, San Diego, California, USA
    J Am Acad Dermatol 59:295-315. 2008
    ..In addition, a list of teratology information resources is included to help practicing clinicians find up-to-date information regarding the safety of the medications they prescribe...